Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 16/20 | 0.81 |
| ▸ | RARB | P10826 | 17/20 | 0.77 |
| ▸ | RARG | P13631 | 12/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240995 | 0.91 | RARA (0.67) | RARARARBRARG | |
| SCHEMBL27491278 | 0.90 | RARA (0.66) | RARARARBRARG | |
| SCHEMBL6237886 | 0.90 | RARA (1.00) | RARARARBRARG | |
| SCHEMBL6239094 | 0.89 | RARA (0.69) | RARARARBRARG | |
| SCHEMBL6239917 | 0.87 | RARB (1.00) | RARARARBRARG | |
| SCHEMBL13979648 | 0.86 | RARA (0.61) | RARARARBRARG | |
| SCHEMBL27463421 | 0.82 | RARA (0.58) | RARARARBRARG | |
| SCHEMBL8331012 | 0.82 | RARB (0.72) | RARARARBRARG | |
| SCHEMBL6238844 | 0.82 | RARA (0.78) | RARARARBRARG | |
| SCHEMBL7627172 | 0.81 | RARA (0.64) | RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11648223-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-05-16 | — | — | US | disclosed |
| CN-115671292-A | Receptor selective retinoid and rexinoid compounds and immunomodulators for cancer immunotherapy | IO治疗公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-109310763-B | Receptor selective retinoid and rexinoid compounds and immunomodulators for cancer immunotherapy | IO治疗公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20220184012-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2022-06-16 | — | — | US | disclosed |
| US-20200390731-A1 | MANIPULATION OF THE RETINOIC ACID SIGNALING PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-12-17 | — | — | US | disclosed |
| US-20170354623-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2017-12-14 | — | — | US | disclosed |
| US-6942980-B1 | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities | ALLERGAN, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1535919-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Allergan, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20020156054-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | ALLERGAN, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6469028-B1 | ARYL-SUBSTITUTED AND ARYL AND (3-OXO-1-PROPENLY)-SUBSTITUTED BENZOPYRAN, BENZOTHIOPYRAN, 1,2-DIHYDROQUINOLINE, AND 5,6-DIHYDRONAPHTHALENE DERIVATIVES | ALLERGAN, INC. | 2002-10-22 | — | — | US | disclosed |
| US-6218128-B1 | DRUG SCREENING FOR INVERSE AGONIST BY MONITORING BINDING OF TWO POLYPEPTIDES HAVING SPECIFIC DOMAINS IN PRESENCE OF TEST COMPOUND | ALLERGAN SALES, INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1042313-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY | Allergan Sales, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6090810-A | SIDE EFFECT REDUCTION | ALLERGAN SALES, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0991636-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | Allergan Sales, Inc. (US) | 2000-04-12 | — | — | EP | disclosed |
| US-6008204-A | ANTIDOTES FOR PREVENTING CERTAIN UNDESIRED SIDE EFFECTS OF RETINOIDS | ALLERGAN SALES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0931786-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Vision Pharmaceuticals L.P. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999033821-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998058922-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | ALLERGAN SALES, INC. (US) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354623-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
| US-20220184012-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
| US-20200390731-A1 | MANIPULATION OF THE RETINOIC ACID SIGNALING PATHWAY | RARB, RARA, RARG | RARA 2/4885RARB 1/4885RARG 3/4885 |
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRG, RXRA, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
| US-20020156054-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | RXRA, RARA, RXRG | RARA 2/4885RARB 7/4885RARG 4/4885 |
| US-11648223-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.